Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-30

FDA Approved: QUVIVIQ — Supplemental Application (Idorsia Pharmaceuticals Ltd)

View source ↗

Summary

FDA approved a supplemental application for QUVIVIQ (daridorexant) from Idorsia Pharmaceuticals Ltd, updating the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QUVIVIQ (daridorexant)

Snippet

SUPPL AP for QUVIVIQ (DARIDOREXANT)